tetano
Editor, Senior Moderator
Int J Audiol
. 2022 May 5;1-5.
doi: 10.1080/14992027.2022.2056721. Online ahead of print.
Four cases of audio-vestibular disorders related to immunisation with SARS-CoV-2 mRNA vaccines
Pierre Ekobena[SUP] 1 [/SUP], Laura E Rothuizen[SUP] 1 [/SUP], Francesca Bedussi[SUP] 2 [/SUP], Pierre Guilcher[SUP] 3 [/SUP], Sylvain Meylan[SUP] 4 [/SUP], Alessandro Ceschi[SUP] 2 [/SUP], François Girardin[SUP] 1 [/SUP], Kim Dao[SUP] 1 [/SUP]
Affiliations
Abstract
Objective: To gain medical insight into the clinical course and safety of otolaryngologic disorders following immunisation with severe acute respiratory coronavirus (SARS-CoV-2) mRNA-based vaccines.
Design: Case description.
Study sample: We report four cases of transient audio-vestibular symptoms, which occurred shortly after inoculation of two BNT162b2 (Pfizer-BioNTech[SUP]®[/SUP]) and mRNA-1273 (Moderna®) vaccines.
Results: Hearing loss was unilateral in all cases and recovered at least partially: it was associated with persistent gait instability in two cases, after 1 and 7 months. Trigger mechanisms underpinning audio-vestibular impairment remain uncertain. Immune tolerance mechanisms with off-target innate activation of T-lymphocytes may be involved in vestibulocochlear nerve disorders, as for other cranial nerves involvement.
Conclusions: The occurrence of audio-vestibular manifestations following mRNA-based vaccines needs ENT monitoring to support their causality in such rare vaccine-related adverse events. Audio-vestibular disorders appeared of transitory nature, including hearing loss, and should not deter further efforts in large-scale vaccination campaigns against SARS-CoV-2.
Keywords: Adverse event; COVID-19 mRNA vaccines; hearing loss; immunisation; sensorineural; vestibular neuritis.
. 2022 May 5;1-5.
doi: 10.1080/14992027.2022.2056721. Online ahead of print.
Four cases of audio-vestibular disorders related to immunisation with SARS-CoV-2 mRNA vaccines
Pierre Ekobena[SUP] 1 [/SUP], Laura E Rothuizen[SUP] 1 [/SUP], Francesca Bedussi[SUP] 2 [/SUP], Pierre Guilcher[SUP] 3 [/SUP], Sylvain Meylan[SUP] 4 [/SUP], Alessandro Ceschi[SUP] 2 [/SUP], François Girardin[SUP] 1 [/SUP], Kim Dao[SUP] 1 [/SUP]
Affiliations
- PMID: 35510657
- DOI: 10.1080/14992027.2022.2056721
Abstract
Objective: To gain medical insight into the clinical course and safety of otolaryngologic disorders following immunisation with severe acute respiratory coronavirus (SARS-CoV-2) mRNA-based vaccines.
Design: Case description.
Study sample: We report four cases of transient audio-vestibular symptoms, which occurred shortly after inoculation of two BNT162b2 (Pfizer-BioNTech[SUP]®[/SUP]) and mRNA-1273 (Moderna®) vaccines.
Results: Hearing loss was unilateral in all cases and recovered at least partially: it was associated with persistent gait instability in two cases, after 1 and 7 months. Trigger mechanisms underpinning audio-vestibular impairment remain uncertain. Immune tolerance mechanisms with off-target innate activation of T-lymphocytes may be involved in vestibulocochlear nerve disorders, as for other cranial nerves involvement.
Conclusions: The occurrence of audio-vestibular manifestations following mRNA-based vaccines needs ENT monitoring to support their causality in such rare vaccine-related adverse events. Audio-vestibular disorders appeared of transitory nature, including hearing loss, and should not deter further efforts in large-scale vaccination campaigns against SARS-CoV-2.
Keywords: Adverse event; COVID-19 mRNA vaccines; hearing loss; immunisation; sensorineural; vestibular neuritis.